These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11350019)

  • 21. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
    Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL; Resnick NM; Parker RA
    J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis.
    Husek P; Svagera Z; Vsianský F; Franeková J; Simek P
    Clin Chem Lab Med; 2008; 46(10):1391-7. PubMed ID: 18844493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
    J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
    J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.
    Delmas PD; Schlemmer A; Gineyts E; Riis B; Christiansen C
    J Bone Miner Res; 1991 Jun; 6(6):639-44. PubMed ID: 1887826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
    N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
    Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture.
    McLaren AM; Hordon LD; Bird HA; Robins SP
    Ann Rheum Dis; 1992 May; 51(5):648-51. PubMed ID: 1616331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men.
    Fall PM; Kennedy D; Smith JA; Seibel MJ; Raisz LG
    Osteoporos Int; 2000; 11(6):481-5. PubMed ID: 10982162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibody assay for free urinary pyridinium cross-links.
    Gomez B; Ardakani S; Evans BJ; Merrell LD; Jenkins DK; Kung VT
    Clin Chem; 1996 Aug; 42(8 Pt 1):1168-75. PubMed ID: 8697572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
    Denk E; Hillegonds D; Hurrell RF; Vogel J; Fattinger K; Häuselmann HJ; Kraenzlin M; Walczyk T
    J Bone Miner Res; 2007 Oct; 22(10):1518-25. PubMed ID: 17576167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of bone resorption by divided-dose calcium supplementation in early postmenopausal women.
    Scopacasa F; Need AG; Horowitz M; Wishart JM; Morris HA; Nordin BE
    Calcif Tissue Int; 2000 Dec; 67(6):440-2. PubMed ID: 11289691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
    Majkić-Singh N; Ilić M; Ignjatović S; Aleksandra-Postić-Grujin
    Clin Lab; 2002; 48(7-8):407-13. PubMed ID: 12146575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate in the treatment of osteoporosis.
    Adami S
    Aging (Milano); 1998 Apr; 10(2):159-60. PubMed ID: 9666215
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R
    J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimes in post-menopausal women: preliminary report on a comparative study].
    Ulla MR; Araujo GL; Giglione F; Fajreldines F; Domingo P; Noriega R; Rivoira MA
    Medicina (B Aires); 1997; 57 Suppl 1():49-55. PubMed ID: 9567355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.